A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The biopharmaceutical industry is grappling with a profound challenge: the silent erosion of critical process knowledge, particularly "tacit knowledge," during…
Read More
What if psilocybin works about as well for depression as an SSRI?
The burgeoning optimism surrounding classic psychedelics as a transformative treatment for depression is beginning to face a crucial reality check.…
Read More
Diabetes to MASH: The Specimens Behind GLP-1’s Widening Roster
The therapeutic landscape for metabolic disorders, and increasingly, a spectrum of other complex diseases, is undergoing a profound transformation, largely…
Read More
Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic diseases is undergoing a profound transformation, heralded by the recent approval of orforglipron, the first…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) initiated CancerLinQ, a pioneering platform designed with the…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The landscape of generic drug economics in the United States is undergoing a significant transformation, largely driven by the advent…
Read More
Insuring the Trip: An Underwriter on What It Will Take for Approved Psilocybin to Become a Real Business
More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, classified psilocybin as a…
Read More
PharmSci 360 2026 heads to New Orleans this October
The American Association of Pharmaceutical Scientists (AAPS) has announced that its premier annual gathering, PharmSci 360, will convene from October…
Read MoreYOU MAY HAVE MISSED
